Abstract 3249
Background
Cabozantinib (cabo) is a potent VEGFR-TKI currently approved in mRCC as a standard of care in second line or beyond. However, the incidence of grade 3-4 weight loss (WL) reported in pivotal trial seems underestimated. The aim was to evaluate the weight loss in real life under cabo.
Methods
All consecutive mRCC patients treated with cabo at a single institution from January 2014 to August 2018 were included. Patients with ascite/oedema were excluded. Weight was evaluated every month under cabo. Toxicities that may influence weight loss as diarrhea, nausea, anorexia, stomatite were collected. Individual profile, weigh change from baseline and time to first grade 2 WL(> 10%) and grade 3 WL(>20%) were described; disease control rate (CR+PR+SD) and objective response rate (CR+PR) according to RECIST 1.1. We analysed Grade 1, 2, 3 WL at 1, 3 and 6 months in patients without progression disease beyond 6 months of cabo.
Results
From 102 patients receiving cabo, 91 patients with a median follow-up of a 15.9 months [range: 1.2-58.7] were included: 69.2% male, median age: 62.0 [28.0-78.0] years and median baseline BMI: 24.8 [16.6-49.3] kg/m2. IMDC score was good, intermediate and poor in 12 (13.5%), 58 (65.2%) and 19 (21.4%), respectively. Median cabo treatment duration was 10.4 months [1-26.9]. At study cut off, n = 37 (40.7%) patients are still on treatment, 39 (42.9%) stopped cabo for disease progression and 15 (16.5%) for toxicity. Overall, 32 patients (35.1%) had more than 10% WL (grade 2) from baseline including 10 patients (11%) with more than 20% WL (grade ≥ 3). DCR was 96.4 [95%CI 89.8-99.3] and ORR was 34.9% [95%CI 24.8-46.2]. Median overall survival was 20.3 months. In responders to cabo more than 6 months (n = 59), cumulative incidence of grade 2 and grade 3 WL were respectively: 44.1% (n = 26) and 13.6% (n = 8). Median time to first grade 2 WL was 11.9 months. In this group, 11.3%, 42.9%, 47.6% of patients lost weigh more than 5% at 1, 3, 6 month compared to baseline under cabo.
Conclusions
Significant weight loss with cabozantinib is undereported in clinical trials compared to real world setting. It requires investigations and early management to anticipate sarcopenia in patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Colomba: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (institution), Advisory / Consultancy: SANOFI. B. Raynard: Advisory / Consultancy, Research grant / Funding (self): Fresenius Kabi. B. Escudier: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: EXELIXIS; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: NOVARTIS; Honoraria (self), Advisory / Consultancy: Pfizer. L. Albiges: Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract